Executive Director, Global Commercial Lead

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team you will join other outstanding Revolutionariesin a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

Reporting to the VP Global Commercial Development Disease Area Lead this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. Candidates should be passionate about leading cross-functional collaboration and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings.

Specifically you will be responsible for:

• Partner across the company including with clinical development medical affairs market access to drive indication strategy shape brand strategies across the product team.

• Ensure global readiness to drive successful launch planning commercialization and performance tracking across the U.S. and key ex-U.S. markets.

• Execute global disease area strategy brand strategies including branding positioning messaging and value propositions that guide regional affiliates and align with long-term portfolio goals.

• Translate scientific and market insights into compelling strategies launch narratives and execution plans; effectively communicating recommendations and leading strategic discussions with global and regional stakeholders.

• Develop and refine global brand plans including revenue and patient forecasts to inform investment decisions lifecycle strategies and portfolio prioritization.

• Drive excellence in global launch execution: creating launch frameworks ensuring best practices are shared across affiliates and monitoring progress to anticipate and resolve challenges.

• Identify and manage external agencies vendors and partners to deliver impactful global campaigns educational initiatives and engagement platforms.

• Serve as a trusted resource to executive leadership in identifying opportunities to maximize commercial value expand indications and differentiate in competitive markets.

• Bring innovation and new capabilities to global marketingcollaborate with IS Commercial to integrate digital omnichannel and data-driven approaches to build a best-in-class commercial function.

• Up to 50% of travel required.

Required Skills Experience and Education:

• Bachelors degree required (MBA preferred) with at least 15 years of progressive commercial experience in a biotechnology and/or pharmaceutical company including strategic marketing and ideally sales.

• Proven success of developing and executing global marketing strategy.

• Experience in leading the global launch of new product in competitive spaces.

• Demonstrated ability to derive insights/analytics leading to the development of innovative marketing strategies.

• Strong leadership with the ability to lead teams work well cross-functionally and influence across the organization to create a clear sense of direction.

• Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines.

• Ability to represent Revolution Medicines well externally: strong interpersonal skills including verbal and written communication.

• Entrepreneurial mindset with a tolerance for ambiguity and a passion for helping cancer patients.

Preferred Skills:

• Experience with an oncology launch is desired.

• Prior experience in a smaller rapidly growing company.

• Experience in gastrointestinal or lung cancer preferred. #LI-Hybrid #LI-SS2